Palisade Bio, Inc. (PALI) - Latest Market Data

Price & Market Data

Price: $1.93

Daily Change: -$0.08 / 4.15%

Daily Range: $1.90 - $2.07

Market Cap: $338,870,368

Daily Volume: 3,260,517

Performance Metrics

1 Week: 10.00%

1 Month: -29.29%

3 Months: 19.28%

6 Months: -15.38%

1 Year: 167.6%

YTD: -15.74%

About Palisade Bio, Inc. (PALI)

Comprehensive analysis of Palisade Bio, Inc. (PALI). Currently at 1.93, with a daily change of -$0.08 / 4.15%. Market cap: 338,870,368. Evaluate its performance over YTD, 1-month, and 6-month periods.

Company Details

Employees: 14

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Selected stocks

Evolution Petroleum Corporation, Inc. (EPM)

Rein Therapeutics, Inc. (RNTX)

Lipocine Inc. (LPCN)

Innate Pharma S.A. (IPHA)

La Rosa Holdings Corp. (LRHC)